Cargando…

Clinical validation of controlled exposure to house dust mite in the environmental exposure unit (EEU)

RATIONALE: The Environmental Exposure Unit (EEU), a controlled allergen exposure model of allergic rhinitis (AR), has traditionally utilized seasonal allergens. We sought to clinically validate the use of house dust mite (HDM), a perennial allergen, in the HDM-EEU, a specially designed facility with...

Descripción completa

Detalles Bibliográficos
Autores principales: Hossenbaccus, Lubnaa, Linton, Sophia, Thiele, Jenny, Steacy, Lisa, Walker, Terry, Malone, Crystal, Ellis, Anne K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7995585/
https://www.ncbi.nlm.nih.gov/pubmed/33771217
http://dx.doi.org/10.1186/s13223-021-00536-3
_version_ 1783669946798047232
author Hossenbaccus, Lubnaa
Linton, Sophia
Thiele, Jenny
Steacy, Lisa
Walker, Terry
Malone, Crystal
Ellis, Anne K.
author_facet Hossenbaccus, Lubnaa
Linton, Sophia
Thiele, Jenny
Steacy, Lisa
Walker, Terry
Malone, Crystal
Ellis, Anne K.
author_sort Hossenbaccus, Lubnaa
collection PubMed
description RATIONALE: The Environmental Exposure Unit (EEU), a controlled allergen exposure model of allergic rhinitis (AR), has traditionally utilized seasonal allergens. We sought to clinically validate the use of house dust mite (HDM), a perennial allergen, in the HDM-EEU, a specially designed facility within the larger EEU. METHODS: Forty-four HDM-allergic and eleven non-allergic participants were screened and deemed eligible for one of two 3-h exposure sessions in the HDM-EEU. Participants were exposed to a modest or higher HDM target, with blood and nasal brushing samples collected before and after allergen exposure. Symptomatic data, including Total Nasal Symptom Score (TNSS), Total Ocular Symptom Score (TOSS), Total Rhinoconjunctivitis Symptom Score (TRSS), and Peak Nasal Inspiratory Flow (PNIF) were collected at baseline, every 30 min until 3 h, on an hourly basis for up to 12 h, and at 24 h following the onset of HDM exposure. RESULTS: The modest and higher HDM target sessions respectively featured cumulative total particle counts of 156,784 and 266,694 particles (2.5–25 µm), Der f 1 concentrations of 2.67 ng/m(3) and 3.80 ng/m(3), and Der p 1 concentrations of 2.07 ng/m(3) and 6.66 ng/m(3). Allergic participants experienced an increase in symptoms, with modest target participants plateauing at 1.5 to 2 h and achieving a mean peak TNSS of 5.74 ± 0.65, mean peak TOSS of 2.47 ± 0.56, and mean peak TRSS of 9.16 ± 1.32. High HDM-target allergics reached a mean peak TNSS of 8.17 ± 0.71, mean peak TOSS of 4.46 ± 0.62, and mean peak TRSS of 14.08 ± 1.30 at 3 h. All allergic participants’ symptoms decreased but remained higher than baseline after exiting the HDM-EEU. Sixteen participants (37.2%) were classified as Early Phase Responders (EPR), eleven (25.6%) as protracted EPR (pEPR), seven (16.3%) as Dual Phase Responders (DPR), and nine (20.9%) as Poor Responders (PR). Allergic participants experienced significant percent PNIF reductions at hours 2 and 3 compared to healthy controls. Non-allergics were asymptomatic during the study period. CONCLUSIONS: The HDM-EEU is an appropriate model to study HDM-induced AR as it can generate clinically relevant AR symptoms amongst HDM-allergic individuals.
format Online
Article
Text
id pubmed-7995585
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-79955852021-03-26 Clinical validation of controlled exposure to house dust mite in the environmental exposure unit (EEU) Hossenbaccus, Lubnaa Linton, Sophia Thiele, Jenny Steacy, Lisa Walker, Terry Malone, Crystal Ellis, Anne K. Allergy Asthma Clin Immunol Research RATIONALE: The Environmental Exposure Unit (EEU), a controlled allergen exposure model of allergic rhinitis (AR), has traditionally utilized seasonal allergens. We sought to clinically validate the use of house dust mite (HDM), a perennial allergen, in the HDM-EEU, a specially designed facility within the larger EEU. METHODS: Forty-four HDM-allergic and eleven non-allergic participants were screened and deemed eligible for one of two 3-h exposure sessions in the HDM-EEU. Participants were exposed to a modest or higher HDM target, with blood and nasal brushing samples collected before and after allergen exposure. Symptomatic data, including Total Nasal Symptom Score (TNSS), Total Ocular Symptom Score (TOSS), Total Rhinoconjunctivitis Symptom Score (TRSS), and Peak Nasal Inspiratory Flow (PNIF) were collected at baseline, every 30 min until 3 h, on an hourly basis for up to 12 h, and at 24 h following the onset of HDM exposure. RESULTS: The modest and higher HDM target sessions respectively featured cumulative total particle counts of 156,784 and 266,694 particles (2.5–25 µm), Der f 1 concentrations of 2.67 ng/m(3) and 3.80 ng/m(3), and Der p 1 concentrations of 2.07 ng/m(3) and 6.66 ng/m(3). Allergic participants experienced an increase in symptoms, with modest target participants plateauing at 1.5 to 2 h and achieving a mean peak TNSS of 5.74 ± 0.65, mean peak TOSS of 2.47 ± 0.56, and mean peak TRSS of 9.16 ± 1.32. High HDM-target allergics reached a mean peak TNSS of 8.17 ± 0.71, mean peak TOSS of 4.46 ± 0.62, and mean peak TRSS of 14.08 ± 1.30 at 3 h. All allergic participants’ symptoms decreased but remained higher than baseline after exiting the HDM-EEU. Sixteen participants (37.2%) were classified as Early Phase Responders (EPR), eleven (25.6%) as protracted EPR (pEPR), seven (16.3%) as Dual Phase Responders (DPR), and nine (20.9%) as Poor Responders (PR). Allergic participants experienced significant percent PNIF reductions at hours 2 and 3 compared to healthy controls. Non-allergics were asymptomatic during the study period. CONCLUSIONS: The HDM-EEU is an appropriate model to study HDM-induced AR as it can generate clinically relevant AR symptoms amongst HDM-allergic individuals. BioMed Central 2021-03-26 /pmc/articles/PMC7995585/ /pubmed/33771217 http://dx.doi.org/10.1186/s13223-021-00536-3 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Hossenbaccus, Lubnaa
Linton, Sophia
Thiele, Jenny
Steacy, Lisa
Walker, Terry
Malone, Crystal
Ellis, Anne K.
Clinical validation of controlled exposure to house dust mite in the environmental exposure unit (EEU)
title Clinical validation of controlled exposure to house dust mite in the environmental exposure unit (EEU)
title_full Clinical validation of controlled exposure to house dust mite in the environmental exposure unit (EEU)
title_fullStr Clinical validation of controlled exposure to house dust mite in the environmental exposure unit (EEU)
title_full_unstemmed Clinical validation of controlled exposure to house dust mite in the environmental exposure unit (EEU)
title_short Clinical validation of controlled exposure to house dust mite in the environmental exposure unit (EEU)
title_sort clinical validation of controlled exposure to house dust mite in the environmental exposure unit (eeu)
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7995585/
https://www.ncbi.nlm.nih.gov/pubmed/33771217
http://dx.doi.org/10.1186/s13223-021-00536-3
work_keys_str_mv AT hossenbaccuslubnaa clinicalvalidationofcontrolledexposuretohousedustmiteintheenvironmentalexposureuniteeu
AT lintonsophia clinicalvalidationofcontrolledexposuretohousedustmiteintheenvironmentalexposureuniteeu
AT thielejenny clinicalvalidationofcontrolledexposuretohousedustmiteintheenvironmentalexposureuniteeu
AT steacylisa clinicalvalidationofcontrolledexposuretohousedustmiteintheenvironmentalexposureuniteeu
AT walkerterry clinicalvalidationofcontrolledexposuretohousedustmiteintheenvironmentalexposureuniteeu
AT malonecrystal clinicalvalidationofcontrolledexposuretohousedustmiteintheenvironmentalexposureuniteeu
AT ellisannek clinicalvalidationofcontrolledexposuretohousedustmiteintheenvironmentalexposureuniteeu